ION582

Ionis Pharmaceuticals reports Q3 2024 financial results, highlighting progress with WAINUA U.S. launch, olezarsen FDA action date in Dec 2024, and donidalorsen HAE PDUFA Aug 2025. The company reaffirms 2024 P&L financial guidance and increases cash guidance to $2.2 billion. Key pipeline milestones include Phase 3 data for olezarsen's second indication and pelacarsen in Lp(a)-driven cardiovascular disease expected in 2025, and ION582 for Angelman syndrome entering Phase 3 development in H1 2025.

Ionis Pharmaceuticals announces successful Phase 2 discussion with FDA, aligning on Phase 3 design for ION582, targeting Angelman syndrome. Bayley-4 expressive communication selected as primary endpoint, with Phase 3 study initiation planned for H1 2025. Ionis to update ION582 program at FAST Global Science Summit in November.